NASDAQ:DMPI - DelMar Pharmaceuticals Stock Price, Forecast & News

DelMar Pharmaceuticals trades on the NASDAQ under the ticker symbol "DMPI."

Shares of DelMar Pharmaceuticals reverse split before market open on Wednesday, May 8th 2019. The 1-10 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of DelMar Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) posted its quarterly earnings results on Tuesday, September, 10th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.59. View DelMar Pharmaceuticals' Earnings History.

DelMar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for DelMar Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DelMar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DelMar Pharmaceuticals.

Media headlines about DMPI stock have trended extremely negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DelMar Pharmaceuticals earned a daily sentiment score of -4.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for DelMar Pharmaceuticals.

DelMar Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 241,800 shares, an increase of 270.3% from the October 31st total of 65,300 shares. Based on an average trading volume of 568,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 9.9% of the company's stock are sold short. View DelMar Pharmaceuticals' Current Options Chain.

Some companies that are related to DelMar Pharmaceuticals include Kazia Therapeutics (KZIA), ProPhase Labs (PRPH), Eyegate Pharmaceuticals (EYEG), Q BioMed (QBIO), Soligenix (SNGX), Provectus Biopharmaceuticals (PVCT), Aerpio Pharmaceuticals (ARPO), Melinta Therapeutics (MLNT), Acerus Pharmaceuticals (TRLPF), OncoSec Medical (ONCS), Bio-Path (BPTH), Unum Therapeutics (UMRX), BIOLINERX LTD/S (BLRX), China SXT Pharmaceuticals (SXTC) and AzurRx BioPharma (AZRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other DelMar Pharmaceuticals investors own include Advanced Micro Devices (AMD), Sunworks (SUNW), Medical Properties Trust (MPW), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), BIOLINERX LTD/S (BLRX), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

DelMar Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (8.35%). View Institutional Ownership Trends for DelMar Pharmaceuticals.

DMPI stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for DelMar Pharmaceuticals.

Shares of DMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DMPI stock can currently be purchased for approximately $0.62.

DelMar Pharmaceuticals has a market capitalization of $7.07 million. The company earns $-8,050,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. DelMar Pharmaceuticals employs 4 workers across the globe.View Additional Information About DelMar Pharmaceuticals.

The official website for DelMar Pharmaceuticals is http://www.delmarpharma.com/.

DelMar Pharmaceuticals' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-350-4364 or via email at [email protected]